论文部分内容阅读
目的 :研究哌拉西林 /他佐巴坦治疗难治性自发性细菌性腹膜炎的临床疗效及其安全性。方法 :71例自发性细菌性腹膜炎病人随机分为观察组 36例 ,以哌拉西林 /他佐巴坦 4 .5 g静滴 ,Q8h ;对照组 35例 ,以头孢曲松 2 .0g静滴 ,Q8h ,疗程均为 10～ 14d。结果 :观察组与对照组各有 34例、31例完成研究 ,其临床有效率和显效率分别为 (94 .12 % )、(91.18% )和 (87.10 % )、(6 1.2 9% ) ,显效率差异有统计学意义 (P =0 .0 0 4 ) ,主要症状恢复时间观察组短于对照组 (P <0 .0 0 1)。结论 :哌拉西林 /他佐巴坦能高效、安全治疗难治性自发性细菌性腹膜炎 ,临床疗效优于头孢曲松。
Objective: To study the clinical efficacy and safety of piperacillin / tazobactam in the treatment of refractory spontaneous bacterial peritonitis. Methods: Seventy-one patients with spontaneous bacterial peritonitis were randomly divided into observation group (n = 36), piperacillin / tazobactam (n = 4.5), Q8h and control group (n = 35) , Q8h, treatment are 10 ~ 14d. Results: The study group and the control group had 34 cases each and 31 cases completed the study. The clinical effective rate and the markedly effective rate were 94.12%, 91.18% and 87.10% respectively, Significant differences were statistically significant (P = 0.040), the main symptom recovery time observation group was shorter than the control group (P <0. Conclusion: Piperacillin / tazobactam is superior to ceftriaxone in the treatment of refractory spontaneous bacterial peritonitis with high efficiency and safety.